High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study) [version 1; referees: 2 approved]
Background: Tuberculous meningitis (TBM) has 44% (95%CI 35-52%) in-hospital mortality with standard therapy in Uganda. Rifampicin, the cornerstone of TB therapy, has 70% oral bioavailability and ~10-20% cerebrospinal fluid (CSF) penetration. With current WHO-recommended TB treatment containing 8-12...
Main Authors: | Fiona V. Cresswell, Kenneth Ssebambulidde, Daniel Grint, Lindsey te Brake, Abdul Musabire, Rachel R. Atherton, Lillian Tugume, Conrad Muzoora, Robert Lukande, Mohammed Lamorde, Rob Aarnoutse, David Meya, David R. Boulware, Alison M. Elliott |
---|---|
Format: | Article |
Language: | English |
Published: |
Wellcome
2018-07-01
|
Series: | Wellcome Open Research |
Online Access: | https://wellcomeopenresearch.org/articles/3-83/v1 |
Similar Items
-
Utility of the Xpert MTB/RIF assay for diagnosis of tuberculous meningitis.
by: David R Boulware
Published: (2013-10-01) -
Tuberculous meningitis diagnosis and outcomes during the Xpert MTB/Rif era: a 6.5-year cohort study in Uganda [version 2; referees: 1 approved, 2 approved with reservations]
by: Fiona V. Cresswell, et al.
Published: (2018-07-01) -
Xpert MTB/RIF Ultra for Tuberculosis Testing in Children: A Mini-Review and Commentary
by: Rachel R. Atherton, et al.
Published: (2019-02-01) -
Detection of Mycobacterium tuberculosis in urine by Xpert MTB/RIF Ultra: A useful adjunctive diagnostic tool in HIV-associated tuberculosis
by: Rachel R. Atherton, et al.
Published: (2018-10-01) -
Management of false-positive rifampicin resistant Xpert MTB/RIF
by: Natalie Beylis, et al.
Published: (2020-10-01)